According to Desktop Health, the production-grade medical 3D printing sub-brand of Desktop Metal, the first patients have been treated with CMFlex, an off-the-shelf 3D printed synthetic bone graft product developed and manufactured by Chicago-based Dimension Inx on the 3D-Bioplotter.
Founded in 2017, Dimension Inx is a regenerative therapeutics company that designs, develops, and manufactures therapeutic products to restore tissue and organ function. The company owns four Desktop Health 3D-Bioplotters – two for R&D and two for manufacturing their commercial CMFlex product.
Dimension Inx received FDA clearance for CMFlex in December of 2022. CMFlex is currently available to a limited number of key surgeons with a broader release to follow later in 2024.
The first synthetic bone grafts jaw cases were performed by Dr. Derek Steinbacher, Director of West River Surgery Center, former Professor of Plastic surgery and Chief of Oral and Maxillofacial surgery at Yale New Haven Health, and Dr. Brian Farrell, DDS, MD, of the Carolinas Center for Oral & Facial Surgery. Procedures performed included a mandibular angle augmentation (surgery of the lower jaw) and maxillary segmental osteotomy (surgery of the upper jaw).
CMFlex has also been used in dental socket preservation surgeries for future dental implant placement by Dr. Robert Bosack, DDS, from Oral, Maxillofacial & Dental Implant Surgery.
“These first cases are not only indicative of a new generation of biomaterials, but also highlight our technology platform’s unique capability to rapidly create biomaterials that direct cell behavior to restore tissue and organ function. It is a proud moment for us to be able to demonstrate the value of therapeutics derived from integrating novel biomaterial design and 3D printing approaches,” said Dr. Adam Jakus, Co-founder, CTO, and Head of Technology Strategy, at Dimension Inx.
“We’re excited by the interest we’ve already received from surgeons who recognize the importance of a ready-to-use solution with great handling characteristics and the ability to cut and shape the graft to match the defect site,” said Dr. Ramille Shah, Co-founder, CSO, and Head of R&D at Dimension Inx.
